Antibody‐directed enzyme prodrug therapy: A review

Drug Development Research

Volumn 34, Issue 2, 1995, Pages 220-230

  Bagshawe, Kenneth D ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

antibodies; enzymes; prodrug; tumor

Indexed keywords

4 [(2 CHLOROETHYL)[2 MESYLOXYETHYL]AMINO]BENZOYL GLUTAMIC ACID; ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOSPORIN; ENZYME; NITROSOUREA DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

CANCER; CONJUGATION; DRUG CLEARANCE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; NONHUMAN; REVIEW;

EID: 0028963579     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430340211     Document Type: Article

References (82)

1. Cephalosporin nitrogen mustard carbamate prodrugs for ADEPT
2. Disposition of the prodrug 4‐(bis(2‐chloroethyl)amino) benzoyl‐l‐glutamic acid and its active parent drug in mice
3. Antibody directed enzymes revive anti‐cancer prodrugs concept
4. Towards generating cytotoxic agents at cancer sites
5. Antibody‐directed enzyme prodrug therapy (ADEPT). Clinical report
6. Antibody‐directed enzyme prodrug therapy (ADEPT)
7. A cytotoxic agent can be generated selectively at cancer sites
8. Monoclonal antibodies in cancer treatment
9. 131I antibody to human chorionic gonadotrophin:Preliminary communication
10. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer
11. N‐(4'‐hydroxyphenyl acetyl) palytoxin: A palytoxin prodrug that can be activated by a monoclonal antibody‐penicillin G amidase conjugate
12. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation
13. Factors influencing variability of localisation of antibodies to CEA in patients with colorectal carcinoma
14. Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumours
15. Induction of carcinoembryonic antigen secretion and modulation of protein secretion/expression and fironectin/laminin expression in human colon carcinoma cells by transforming growth factor β1
16. Phage libraries for generation of clinically useful antibodies
17. Effects of sodium butyrate on synthesis of human chorionic gonadotrophin in trophoblastic and non‐trophoblastic tumours
18. Intratumour factors influencing the access of antibody to tumour cells
19. Antitumour drugs with latent activity
20. The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody
21. New mustard prodrugs for ADEPT
22. Antibody directed enzyme prodrug therapy causes regression of established breast carcinoma xenografts
23. Antitumour activity of an immunotoxin in a nude mouse model of human ovarian cancer
24. Preclinical studies and clinical correlation of the effect of alkylating dose
25. A modelling analysis of monoclonal antibody percolation through tumours. A binding‐site barrier
26. Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN‐α
27. Univalent antibodies kill tumour cells in vitro and in vivo
28. Demonstration of tumor specific antigens in human colonic carcinomas by immunological tolerance and absorption techniques
29. Use of radiolabelled antibodies to carcinoembryonic antigen for the detection and localisation of diverse cancers by external photoscanning
30. Preclinical and early clinical development of the anti‐CD2 monoclonal antibody IDEC‐C2B8
31. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant Interferon
32. Activation of methotrexate‐α‐alanine by Carboxypeptidase A‐monoclonal antibody conjugate
33. Analysis of a conjugate between anti‐carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for speciic activation of the prodrug etoposide phosphate
34. A monoclonal antibody‐β‐glucuronidase conjugated as activator of the prodrug epirubicin glucuronide for specific treatment of cancer
35. Significance of circulating clearance of tumour localising IgG and F(ab')2 for potential therapy studied in a CEA producing xenograft model
36. Selection of phage antibodies by binding affinity mimicking affinity maturation
37. Sequence specific peptide cleavage catalysed by an antibody
38. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumours. Significance of elevated interstitial pressure
39. Synthetic approaches to biologically active peptides and proteins including enzyms
40. Antibody‐penicillin V‐amidase conjugates kill antigen positive tumour cells when combined with doxorubicin phenoxyacetamide
41. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate
42. A new cytotoxic DBA interstrand cross‐linking agent, 5‐(aziridin‐I‐YL)‐4 hydroxyamino‐2 nitrobenzamide (CB 1954) by a nitro reductase enzyme in Walker carcinoma cells
43. Radiolabelled monoclonal anti‐CEA antibodies for the detection of human colon carcinomas by external photoscanning and immunoscintigraphy
44. Biodistribution of antibodies after intra‐peritoneal and intravenous injection and effect of carbohydrate modification
45. The potential for carboxypeptidase G2 antibody conjugates as anti‐tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model
46. Optimisation of small scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2
47. Tumour necrosis factor increases tumour uptake of co‐administered antibody‐carboxypeptidase G2 conjugate
48. Site‐specific prodrug activation by antibody β‐lactamase conjugates: Regression and long‐term growth inhibition of human colon carcinoma xenograft models
49. Synthesis of prodrugs of Doxorubicin for antibody directed enzyme prodrug therapy
50. Selective destruction of target cells by diphtheria toxin' conjugated to antibody directed against antigens on the cells
51. Galactose‐conjugated antibodies in cancer therapy: Properties and principles of action
52. 131I anti‐CEA antibody in a colonic xenograft model
53. Immunological heterogenity of carcinoembryonic antigen: Immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumours with monoclonal antibodies
54. Antineoplastic glucuronide prodrug treatment of human tumour cells targeted with a monoclonal antibody‐enzyme conjugate
55. Dose‐dependent localisation and potential for therapy of F(ab')2 fragment against CEA studied in a human tumour xenograft model
56. Dose dependent localisation of a monoclonal F(ab')2 fragment against CEA in the mouse xenograft model
57. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs
58. Cytotoxicity following specific activation of amygladin
59. Behaviour of the idiotype network in conventional immune responses. I:Kinetics of idiotypic and anti‐idiotypic antibodies following immunisation with T‐independent and T‐dependent antigens
60. A human choriocarcinoma zenograft in nude mice. A model for the study of antibody localisation
61. Anti‐tumour effects of antibody‐alkaline phosphatase conjugates in combination with etoposide phosphate
62. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody‐alkaline phosphatase conjugates
63. Inactivation and clearance of an anti‐CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model
64. Antibody directed enzyme prodrug therapy (ADEPT): A three phase system
65. Human immune response to monoclonal antibody‐enzyme conjugates in Adept Pilot Clinical Trial
66. Adept: A three phase study in ovarian tumour xenografts
67. Galactosylated antibodies and antibody‐enzyme conjugates in antibody‐directed enzyme prodrug therapy
68. Purification and properties of carboxypeptidase G2 from pseudomonas strain RS 16
69. Increased antitumour effect of immunoconjugates and tumour necrosis factor in vivo
70. Novel analogues of CB 1954: Their potential use in an antibody directed enzyme prodrug therapy (ADEPT) strategy
71. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2
72. Ablation of human choriocarcinoma xenograftin nude mice by antibody‐directed enzyme prodrug therapy (ADEPT) with three novel compounds
73. Endogenous activation of a prodrug in antibody directed enzyme prodrug therapy
74. A novel bisiodo‐phenol mustard in antibody‐directed enzyme prodrug therapy (ADEPT)
75. Monoclonal antibody beta‐lactamase conjugates for the activation of a cephalosporin mustard prodrug
76. Targeting of vascular endothelium in solid tumours
77. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody‐penicillin‐G amidase conjugate
78. Intratumoral generation of 5‐Fluorouracil mediated by an antibody‐cytosine deaminase conjugate in combination with 5‐fluorocytosine
79. Prodrugs in cancer chemotherapy
80. Stimulation of human chorionic gonadotrophin secretion by glucocorticoids
81. Pharmacokinetic analysis of two‐step approaches using bifunctional and enzyme‐conjugated antibodies